The GLP-1 receptor agonist market features a variety of approved and investigational products, including short-acting agonists like exenatide and lixisenatide, long-acting options such as semaglutide, dulaglutide, and liraglutide, as well as oral formulations like oral semaglutide (Rybelsus)
Units Chart for All Doses This comprehensive chart outlines unit conversions for common semaglutide doses across popular compounded concentrations, crucial for precise injection volume without overdose risks
Semaglutide addresses insulin resistance directly, often restoring hormonal balance in PCOS patients
Nausea, vomiting, diarrhea and constipation are common especially as the body is adjusting to higher doses of the drug
Hair thinning has been noted in association with retatrutide, likely related to rapid weight loss triggering telogen effluvium, though a direct pharmacological effect cannot be excluded as alopecia is listed as an adverse reaction with some licensed GLP-1 receptor agonists